Scarica l'app Stockscreener
1.42
2.07%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates - MSN
BioXcel Therapeutics Advances Clinical Trials Amid Financial Adjustments - TipRanks
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | BTAI Stock News - GuruFocus
BioXcel Therapeutics, Inc. SEC 10-Q Report - TradingView
BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BioXcel Therapeutics (BTAI) Reports Major Milestone in BXCL501 T - GuruFocus
BioXcel Therapeutics Q1 2025 Financial Results and Business Update - TradingView
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options - The Globe and Mail
SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
IGALMI Marks Significant Market Growth, Reaching New Heights in Treatment Accessibility | DelveInsight - The Malaysian Reserve
Press Release Distribution & PR Platform - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of BioXcel Therapeutics, Inc.(BTAI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.
BioXcel Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
BioXcel Therapeutics stock hits 52-week low at $1.72 By Investing.com - Investing.com Canada
BioXcel Therapeutics stock hits 52-week low at $1.72 - Investing.com
BioXcel Therapeutics Initiates At-The-Market Equity Program - Investing.com Australia
BioXcel Therapeutics Initiates At-The-Market Equity Program By Investing.com - Investing.com Canada
Bioxcel Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $8.1 Million From Time To Time Through CanaccordSEC Filing - MarketScreener
ROSEN, A RANKED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI - AsiaOne
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates - MSN
BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo
BioXcel Therapeutics Advances Clinical Trials and Reduces Losses - TipRanks
BioXcel Therapeutics Inc. (BTAI) reports earnings - Quartz
BioXcel Therapeutics, Inc. SEC 10-K Report - TradingView
BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioXcel Therapeutics, Inc. Q4 Loss Declines - Nasdaq
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewswire
Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
BioXcel Therapeutics faces potential Nasdaq delisting By Investing.com - Investing.com India
BioXcel Therapeutics (NASDAQ:BTAI) Upgraded at RODMAN&RENSHAW - Defense World
BioXcel Therapeutics faces potential Nasdaq delisting - Investing.com
BIOXCEL THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
BioXcel Therapeutics reports progress in Phase 3 trial By Investing.com - Investing.com South Africa
BioXcel Therapeutics reports progress in Phase 3 trial - Investing.com India
Rodman & Renshaw Initiates Coverage of BioXcel Therapeutics (BTAI) with Buy Recommendation - Nasdaq
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight - Nasdaq
BioXcel Therapeutics boosts cash to $35M for Phase 3 trial - Investing.com Australia
BioXcel Therapeutics boosts cash to $35M for Phase 3 trial By Investing.com - Investing.com South Africa
0.88%
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):